Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse급성 재발의 징후를 나타내는 다발성 경화증을 가진 리툭시맙으로 치료받은 사람에서 BBIBP-CorV COVID-19 백신 접종 후 항-NMDA 수용체 항체 검출Article Published on 2022-12-312022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] added administration Anti-N-methyl-D-aspartate receptor Anti-N-Methyl-d-Aspartate receptor antibodies anti-NMDAR antibodies antibody ataxic Autoimmune Autoimmune encephalitis Babinski sign BBIBP-CorV benefit Case report clinician corticosteroid pulse COVID-19 COVID-19 vaccination CSF analysis detection early diagnosis Encephalitis initiated manifestation MRI multiple sclerosis multiple sclerosis. Neurological symptom NMDAR Patient performed Physical examination plaques positive presenting receiving receptor second dose serum Sinopharm Symptoms tested therapy Vaccines worsening [DOI] 10.1080/21645515.2022.2033540 PMC 바로가기 [Article Type] Article
Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccineArticle Published on 2022-12-232023-07-09 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), [키워드] Autoimmune diseases COVID-19 therapy vaccination. [DOI] 10.1093/rheumatology/keac301 PMC 바로가기
Human Monkeypox-A Global Public Health EmergencyReview Published on 2022-12-142023-06-10 Journal: International Journal of Environmental Research an [Category] Fulltext, 원숭이두창, [키워드] COVID-19 Epidemic Human monkeypox therapy Transmission vaccinia virus zoonosis. [DOI] 10.3390/ijerph192416781 PMC 바로가기 [Article Type] Review
Epigenetic perspectives of COVID-19: Virus infection to disease progression and therapeutic controlResearch article Published on 2022-12-012022-10-05 Journal: Biochimica et biophysica acta. Molecular basis of [Category] COVID19(2023년), SARS, 변종, 신약개발, 유전자 메커니즘, 치료제, [키워드] ACE2 analysed antagonistic autophagy caused Cell cellular metabolism cellular processe Course COVID-19 death Disease progression enzyme Epigenetic epigenetics example expression profile function genes encoding Genome Host host cell IL-6 Infection investigated Laboratory Lipid mechanism membrane metabolic activity metabolic pathway methionine pathogen invasion patients Perspective progression rDNA Regulation replication mechanism ribosome S-adenosylmethionine SARS-CoV-2 sera social isolation the disease the patient therapeutic therapy tissue viral loads virus virus particle virus replication [DOI] 10.1016/j.bbadis.2022.166527 [Article Type] Research article
Non-coding RNA in SARS-CoV-2: Progress toward therapeutic significanceArticle Published on 2022-12-012022-11-15 Journal: International journal of biological macromolecules [Category] COVID19(2023년), SARS, 유전자 메커니즘, 치료제, [키워드] Antiviral biological processe China complications death disease Evidence extreme feasible Giving globe immune reaction increase Infection mechanism Molecular biology ncRNA ncRNAs non-coding RNA noncoding RNA Pathogenesis pathogenic virus preventing infection Progress Research resulting RNA SARS-CoV-2 SARS-CoV2 Spread subsequent Symptoms therapeutic therapy Therapy. virus virus infection [DOI] 10.1016/j.ijbiomac.2022.09.105 PMC 바로가기
3D Ex vivo tissue platforms to investigate the early phases of influenza a virus- and SARS-CoV-2-induced respiratory diseasesArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 신약개발, 진단, 치료제, [키워드] animal model animal models Antiviral Cell Cell culture comparable consequence Drug repurposing drug target early phase Ex vivo ex vivo infection Ex vivo infection model Health Host human lung IAV in vitro Infection Inflammatory cytokine Influenza influenza A virus Influenza virus Innate immunity innate immunity. interferon interferon response Intervention introduced lung tissue morbidity and mortality murine outbreak pathophysiological pharmacological platform Respiratory disease respiratory viruses responses SARS-CoV-2 therapy tissue Treatment viral infection viral life cycle viral replication virus virus while [DOI] 10.1080/22221751.2022.2117101 PMC 바로가기
Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% confidence interval Analysis Baricitinib baseline benefit body mass index combination therapy Concomitant contributed control group coronavirus disease COVID-19 COVID-19 patient COVID-19 patients Day Diabetes Mellitus examined faster greater hazard ratio immunomodulator immunomodulators IMPROVE in both group independent investigated median outcome Oxygen administration Patient patients Prognostic factors Remdesivir respiratory recovery retrospective Retrospective study severity single-center study standard treatment supplemental oxygen survival synergistic therapy Tocilizumab tocilizumab. treated two group [DOI] 10.1002/jmv.28037 PMC 바로가기
The vulnerability of maintenance dialysis patients with COVID-19: mortality and risk factors from a developing countryObservational Study Published on 2022-12-012022-10-04 Journal: Annals of Medicine [Category] 임상, [키워드] age Blood Group Characteristics Clinical features collected data complications country COVID-19 death demographics diabetes dialysis epidemiological Factor General population Haemodialysis hospitalisation ICU admission implementation incidence incidence of COVID-19 increased risk independent risk factor infected patient Infection infection control intensive care intubation Male sex measure Measures Mortality mortality rate mortality rate; multivariable logistic regression old age outcomes Patient patients Peritoneal dialysis peritoneal dialysis. positive Predictive reduce required retrospective risk risk factor risk of infection significantly significantly increased smoking study period tested therapy Vascular venous catheter was used West Bank [DOI] 10.1080/07853890.2022.2075914 PMC 바로가기 [Article Type] Observational Study
COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patientsArticle Published on 2022-12-012022-11-15 Journal: Annals of Medicine [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] addition affecting alleviate antiviral medication antiviral medicine approved Baricitinib Care caused Clinical practice clinical recommendations Community courses COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 treatment COVID-19 treatments Critical deaths develop disease disorder drug Dyspnea effective effective drugs European European Medicines Agency European Union Evidence guidelines. Health healthcare hospital Hospitalization Hospitalized hospitalized patient hypoxia Intervention involved life-threatening lung involvement management Mild moderate molnupiravir monoclonal antibodies monoclonal antibody Most patient Multiorgan dysfunction New outcome public health recommendation Remdesivir Respiratory failure rheumatoid arthritis SARS-CoV-2 Septic shock severe symptom Symptom the disease the patient therapy Thromboembolism Tocilizumab treat Treatment treatment strategy union vaccination [DOI] 10.1080/07853890.2022.2133162 PMC 바로가기
Signs and symptoms of COVID-19 in patients with multiple sclerosisArticle Published on 2022-12-012022-11-16 Journal: European journal of neurology [Category] COVID19(2023년), SARS, 변종, [키워드] affected Ageusia alcohol Analysis Anosmia anti-CD20 therapy association chest pain clinical collected Comorbidity coronavirus disease COVID-19 COVID-19 symptom COVID-19 symptoms Delta Demyelinating diseases difference disease-modifying treatment Factor flu-like symptom Frequency greater identify Infection investigated joint less Linear regression model multiple sclerosis Neurological disorders neurological disorders. number of symptom Occurrence Odds ratio Older outcome Pain Patient Rash recognize risk factor Shortness of breath SIGN similarity smoke smoker Symptom symptoms of COVID-19 Tachycardia therapeutic approach therapy variant [DOI] 10.1111/ene.15554 PMC 바로가기